Company intelligence / Profile preview

Recornea

Trieste, Friuli Venezia Giulia, Italyrecornea.com ↗

Ownership: Private
Development stage: Phase 1

Overview

The company's lead product, the GROSSO® Reshaper—a nitinol intracorneal implant—has completed preclinical studies and entered its first human clinical trial in keratoconus patients in early/mid 2024. The technology aims to restore physiological corneal curvature with predictable outcomes. No published clinical results yet; trials are ongoing. Preclinical animal data has been completed. The glaucoma program remains at a preclinical stage. Recornea received the ESCRS Innovation Award at the Innovation Den in September 2023 for its technology.

Therapeutic areas: Ophthalmology
Modalities: Device (specifically, implantable medical device)Biocompatible and bioenhanced device
Industry: Implantable Medical Devices

Drug pipeline

1 asset

GROSSO

Phase 1

Indications: Keratoconus

Partnerships

Scientifica Venture Capital Fund invested as of June 2024Entrepreneur First SingaporeEntrepreneur First UKGFactorHealth Wildcatters

Beyond the preview

Go deeper on Recornea.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Recornea.

Explore the full profile